+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

M

Actively Recruiting

Healthy Volunteer

Researchers are conducting a multi-center clinical study to assess artificial intelligence AI algorithms for measuring heart function and size using echocardiography. The study aims to compare AI measurements with those of physicians at different experience levels, evaluate the accuracy and stability of AI, and explore its use in complex heart conditions like cardiomyopathy, valve disease, and coronary heart disease. The goal is to improve diagnostic consistency and clinical workflows across medical centers. The study involves measuring cardiac chamber size and function in 1600 participants using AI, senior physicians, and intermediate physicians. All measurements are made with Mindray ultrasonic machines. AI and intermediate physician results are completed within one day after data collection, while senior physician results are completed within one month. The study will establish a standardized reference system for AI-assisted echocardiographic measurements and evaluate AIs performance in special cases. Participants will undergo echocardiographic scans with measurements of left and right ventricular size and function, Doppler ultrasound indicators, and valve annulus displacements. Researchers will analyze data to compare AI and physician measurements, assess measurement deviations, and evaluate AIs efficiency in reducing analysis time. The study will run until July 2026, with ongoing data collection and analysis across multiple centers, aiming to promote wider clinical application of AI technology for cardiovascular disease diagnosis.

Age: 18Years - 80YearsAll Genders
37 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of ATG-022 compared to Investigators Choice treatment in participants with CLDN18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma who have received prior second-line systemic therapy. This Phase III, randomized, controlled, open-label study involves participants with unresectable locally advanced or metastatic disease who have progressed after at least second-line and no more than fourth-line systemic therapy. The study is based on positive earlier data and aims to compare ATG-022 monotherapy with commonly used chemotherapy options. Participants receive either ATG-022 monotherapy at a dose of 1.8 mgkg every 21 days one cycle or Investigators Choice chemotherapy, which includes either Docetaxel or Irinotecan. Docetaxel is administered at 75-100 mgm every 21 days, while Irinotecan is given at 125 mgm on days 1 and 8 every 21 days. The study uses a parallel design to compare these two treatment regimens. Throughout the trial, participants undergo tumor assessments at baseline and then every 6 weeks during treatment, followed by less frequent evaluations after 12 and 24 months until disease progression or death. Survival follow-up occurs every 3 months until death or study end. Researchers measure progression-free survival, overall survival, objective response rate, disease control rate, and duration of response. Laboratory tests and physical examinations are conducted to monitor organ function and safety. Participants remain in the study until disease progression, death, or study completion, with ongoing monitoring of their health.

Age: 18Years +All GendersPhase 3
131 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of LT3001 for treating acute ischemic stroke. This phase II multicenter study compares LT3001 at high and low doses to a placebo, aiming to understand how well LT3001 works and how safe it is for patients who have suffered this type of stroke. The study is led by Shanghai Pharmaceuticals Holding Co., Ltd and involves participants aged 18 to 80 years. Participants will receive LT3001 or placebo through intravenous infusion. The study uses a randomized, double-blind, placebo-controlled design with parallel groups. Treatment must begin within 24 hours after stroke onset. The trial evaluates multiple outcomes, including stroke severity and daily living abilities at various time points up to 90 days after the first dose. During the study, participants will undergo neurological assessments using scales like the NIH Stroke Scale, Modified Rankin Scale, and Barthel Index at several days after treatment. The main safety measure is the occurrence of adverse events, monitored for about two years. Participants will be closely followed to assess recovery progress and any side effects over time.

Age: 18Years - 80YearsAll GendersPhase 2
28 locations